drug · small molecule
elafibranor
Marketedupdated 3mo agoby Ipsen SA🔗 ChEMBL
Approvedcommunity read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for cholangitis and biliary liver cirrhosis and 7 investigational indications.
targets
Peroxisome proliferator-activated receptor alphaPeroxisome proliferator-activated receptor delta
all catalysts(0)
nothing on the calendar yet
Trials studying elafibranor
- phase3A Study of Elafibranor in Adult Japanese Participants With Primary Biliary Cholangitis (PBC)
- phase3A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
- phase3A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
- phase3Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
- phase3A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
- phase2A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
- phase1A Study to Evaluate the Effect of Food on the Level of Circulating Elafibranor in Healthy Participants After Intake of a Single Tablet
- phase1Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jun 10, 2029
~2.8 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (8)
- Mar 30, 2037method-of-use (U-3955)US 11185519
- Mar 30, 2037method-of-use (U-1854)US 11331292
- Mar 30, 2037method-of-use (U-1854)US 11850223
- Mar 30, 2037method-of-use (U-3955)US 11857523
- Mar 30, 2037method-of-use (U-1854)US 12233038
- Mar 30, 2037method-of-use (U-1854)US 12295927
- Mar 30, 2037method-of-use (U-1854)US 12295928
- Mar 30, 2037method-of-use (U-1854)US 12310935
FDA exclusivities (2)
- Jun 10, 2031ODE-486Orphan Drug (7y)4.8y
- Jun 10, 2029NCENew Chemical Entity (5y)2.8y
News(2)
- Regeneron wins FDA approval to challenge Ipsen for rare bone disease marketRegeneron’s Pasatru is the second fibrodysplasia ossificans progressiva drug approved in the U.S., following the 2023 approval of Ipsen’s Sohonos.biospace · 16h ago
- ‘It’s making a difference’: Madrigal CEO talks strategy behind MASH shopping spreeNot content with navigating Rezdiffra’s trajectory to blockbuster territory, Madrigal Pharmaceuticals has spent 2026 shopping for a range of drugs that the company hopes could work alongside its me…fiercebiotech · 20d ago
Data sources
last refreshed 34m ago
Found something off?
comments(0)
5-min edit window · permanent after that